NCT00447577已完成4 期
A Clinical Safety and Efficacy Evaluation of Zylet (Loteprednol Etabonate and Tobramycin Ophthalmic Suspension) vs. Tobradex (Tobramycin and Dexamethasone Ophthalmic Suspension) in the Treatment of Blepharokeratoconjunctivitis
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 276
- 试验地点
- 1
- 主要终点
- The primary efficacy endpoint for this study is the change from baseline to Day 15 in the signs and symptoms composite score
研究概览
简要总结
The objective of this study is to evaluate the safety and efficacy of Zylet vs. Tobradex in the treatment of ocular inflammation associated with blepharokeratoconjunctivitis
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Must be at least 18 years of age
- •Must be able and willing to comply with all treatment and follow up procedures
- •Must have the ability to understand and sign an Informed Consent Form and provide Health Insurance Portability and Accountability Act (HIPAA) authorization
- •Must be able to self-administer drugs
- •Must have a clinical diagnosis of blepharokeratoconjunctivitis in at least one eye (total Ocular Signs and Symptoms score of at least 10, with at least one ocular sign and one ocular symptom each having a score of Grade 2 level or higher)
- •Women of childbearing potential must be sexually inactive or using an approved birth control methods and must have a negative urine pregnancy test
- •Must be willing to discontinue contact lens use for the duration of the study
- •Must have pin-holed Snellen visual acuity equal to or better than 20/40 in both eyes
排除标准
- •Any uncontrolled systemic disease or debilitating disease (e.g. cardiovascular disease, hypertension, diabetes, or cystic fibrosis)
- •Known hypersensitivity to the study drugs or their components (including benzalkonium chloride) or contraindications to tobramycin or ocular corticosteroids
- •Use of any systemic or topical ophthalmic non-steroidal anti-inflammatory agents, analgesics, and antihistamines that cannot be discontinued during the study
- •Use of any topical ophthalmic medications, including tear substitutes, within 2 hours before and that cannot be discontinued during the study
- •Use of any systemic or topical ophthalmic antibiotic agents within 72 hours before and that cannot be discontinued during the study
- •Use of any systemic or topical ophthalmic corticosteroid agents within 7 days before and that cannot be discontinued during the study
- •Use of any systemic or topical ophthalmic mast cell stabilizers within 14 days before and that cannot be discontinued during the study
- •Use of any topical ophthalmic immunosuppressant (e.g. Restasis) agents within 30 days before and that cannot be discontinued during the study
- •Suspected preseptal cellulites, or any other disease conditions which the Investigator determines could interfere with the safety and efficacy evaluations of the study drug
- •Suspected dacrocystitis
- •Participation in an ophthalmic drug or device research study within the 30 days prior to entry in this study
- •Ocular surgery (including laser surgery) in either eye within the past 3 months
研究组 & 干预措施
Zylet
Experimental
Loteprednol etabonate and tobramycin ophthalmic suspension, 0.5%/0.3% (Zylet)
干预措施: Loteprednol etabonate and tobramycin ophthalmic suspension (Drug)
Tobradex
Active Comparator
Tobradex (tobramycin and dexamethasone ophthalmic suspension, 0.3%/0.1%), US marketed product (Alcon) from commercial lots.
干预措施: Tobramycin and dexamethasone ophthalmic suspension (Drug)
结局指标
主要结局
The primary efficacy endpoint for this study is the change from baseline to Day 15 in the signs and symptoms composite score
时间窗: 15 days
次要结局
- The percentage of eyes that were considered improved or cured at each visit based on the Investigator global assessment.(Visit 2, 3 & 4)
- The change from baseline to Day 7 (Visit 3) and to Day 3 (Visit 2) in the signs and symptoms composite score.(Visit 2 & 3)
- The distribution of Investigator global assessment at each visit.(Visit 2, 3 & 4)
- The change from baseline to each visit in the Blepharitis signs composite score, the conjunctivitis signs composite score, and the Keratitis signs composite score.(Visit 1, 2, 3 & 4)
- The change from baseline to each visit in individual signs and symptoms.(Visit 1, 2, 3 & 4)
- VA, Biomicroscopy, and IOP assessments at each visit(Visit 1, 2, 3 & 4)
- Adverse Events(Visit 1, 2, 3 & 4)
- The change from baseline to each visit in the signs composite score and the symptoms composite score.(Visit 1, 2, 3 & 4)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Loteprednol and Tobramycin Versus Tobramycin and Dexamethasone, in the Treatment of BlepharokeratoconjunctivitisKeratitisConjunctivitisBlepharitisNCT01028027Bausch & Lomb Incorporated357
已完成
4 期
Safety and Efficacy of Zylet vs Lotemax, Tobramycin and Vehicle in Pediatric BlepharoconjunctivitisConjunctivitisNCT00705159Bausch & Lomb Incorporated137
已完成
4 期
Pediatric Zylet Safety and Efficacy StudyChalazionHordeolumNCT00420628Bausch & Lomb Incorporated108
已完成
3 期
A Study to Evaluate the Clinical Efficacy and Safety of Tobradex® ST Compared to Azasite® in the Treatment of Subjects With Moderate to Severe Chronic BlepharitisBlepharitisNCT01102244Alcon Research122
已完成
3 期
Study of Intra-articular Injections vs Placebo in Patients With Pain From Osteoarthritis of the KneeOsteoarthritis, KneeNCT01887678Biologische Heilmittel Heel GmbH287